CCNC (cyclin C) is a regulatory component of the Mediator kinase module, a multi-subunit complex that serves as a coactivator for RNA polymerase II-dependent gene transcription 1. CCNC binds to and activates CDK8/19 kinase, which phosphorylates the C-terminal domain of RNA polymerase II to modulate transcription initiation complex formation. The Mediator kinase module functions as a signal transducer, conveying regulatory information from gene-specific transcription factors to the basal transcription machinery 1. Mechanistically, CCNC regulates immune cell function and tumor biology through distinct pathways. In T and NK cells, CCNC deletion enhances effector activity and antitumor potency, associated with increased IL-2 receptor expression and cytokine secretion 23. Conversely, CCNC suppresses CD155 transcription by inhibiting FOSL2 activity; loss of CCNC promotes CD155 upregulation and immune evasion 4. Clinically, CCNC dysregulation associates with cancer progression. CCNC deletions occur in acute lymphoblastic leukemia 5, while elevated CCNC/CDK8 expression correlates with shorter relapse-free survival in breast cancer and reduced chemotherapy response 6. Gene amplification of CCNC occurs in ~10% of breast cancers 6. CCNC polymorphisms associate with pubertal timing variation and subsequent cardiovascular and metabolic disease risk 7. These findings suggest CCNC as both a tumor suppressor and therapeutic target in cancer immunotherapy.